Epidemiologic, Clinical and Immunological Consequences of Co-Infections during Canine Leishmaniosis.
Epidemiologic, Clinical and Immunological Consequences of Co-Infections during Canine Leishmaniosis.
复制标题
DOI:
10.3390/ani11113206
复制
发表时间:
2021-11-10
期刊:
影响因子:
--
通讯作者:
Petersen CA
中科院分区:
文献类型:
--
作者:
Beasley EA;Pessôa-Pereira D;Scorza BM;Petersen CA
Canine leishmaniosis (CanL), the most severe, visceralizing form of disease caused by Leishmania infantum transmitted by phlebotomine sand flies. CanL is frequently diagnosed in the Mediterranean basin and South America, although it is also found in other regions, including the United States (U.S.). Dogs in these regions are at risk for co-infections, prominently tick-borne diseases. Our review examines epidemiologic, clinical, and immunologic mechanisms found during the most common eight CanL co-infections reported in published literature. Co-infections alter immunologic processes and disease progression impacting CanL diagnosis, therapeutic responses, and prognosis. Canine leishmaniosis (CanL) is a vector-borne, parasitic disease. CanL is endemic in the Mediterranean basin and South America but also found in Northern Africa, Asia, and the U.S. Regions with both competent sand fly vectors and L. infantum parasites are also endemic for additional infectious diseases that could cause co-infections in dogs. Growing evidence indicates that co-infections can impact immunologic responses and thus the clinical course of both CanL and the comorbid disease(s). The aim for this review is to summarize epidemiologic, clinical, and immunologic factors contributing to eight primary co-infections reported with CanL: Ehrlichia spp., Anaplasma spp., Borrelia spp., Babesia spp., Trypanosoma cruzi, Toxoplasma gondii, Dirofilaria immitis, Paracoccidioides braziliensis. Co-infection causes mechanistic differences in immunity which can alter diagnostics, therapeutic management, and prognosis of dogs with CanL. More research is needed to further explore immunomodulation during CanL co-infection(s) and their clinical impact.
登录
查看更多内容
影响因子:
5.2
作者:
James MC;Gilbert L;Bowman AS;Forbes KJ
通讯作者:
Forbes KJ
影响因子:
4.4
作者:
Bitsaktsis, C;Huntington, J;Winslow, G
通讯作者:
Winslow, G
影响因子:
3.2
作者:
Attipa, Charalampos;Solano-Gallego, Laia;Tasker, Severine
通讯作者:
Tasker, Severine
影响因子:
3.2
作者:
Attipa C;Hicks CAE;Barker EN;Christodoulou V;Neofytou K;Mylonakis ME;Siarkou VI;Vingopoulou EI;Soutter F;Chochlakis D;Psaroulaki A;Papasouliotis K;Tasker S
通讯作者:
Tasker S
影响因子:
--
作者:
Boggiatto, Paola M.;Ramer-Tait, Amanda E.;Petersen, Christine A.
通讯作者:
Petersen, Christine A.